Heart transplantation research in the next decade--a goal to achieving evidence-based outcomes: National Heart, Lung, And Blood Institute Working Group.
暂无分享,去创建一个
R. Starling | M. Mehra | Mandeep R Mehra | Randall C Starling | M. Shah | Monica R Shah | Lisa Schwartz Longacre | Lisa Schwartz Longacre
[1] P. Sinha,et al. Do donor characteristics really matter? Short- and long-term impact of donor characteristics on recipient survival, 1995-1999. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[2] R. Jennings,et al. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. , 1986, Circulation.
[3] S. Hunt,et al. The changing face of heart transplantation. , 2008, Journal of the American College of Cardiology.
[4] A. Kfoury,et al. Controversies in defining cardiac antibody-mediated rejection: need for updated criteria. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[5] M. Mehra,et al. Current and future challenges in therapy for antibody-mediated rejection. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[6] Ranjit John,et al. Outcomes in cardiac transplant recipients using allografts from older donors versus mortality on the transplant waiting list; Implications for donor selection criteria. , 2004, Journal of the American College of Cardiology.
[7] J. Peart,et al. Sustained cardioprotection: exploring unconventional modalities. , 2008, Vascular pharmacology.
[8] L. Sharples,et al. Deposition of C4d and C3d in cardiac transplants: a factor in the development of coronary artery vasculopathy. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[9] M. Dew,et al. Pulsatile left ventricular assist device support as a bridge to decision in patients with end-stage heart failure complicated by pulmonary hypertension. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[10] C. Porter,et al. Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: a multivariable, multiinstitutional report. The Cardiac Transplant Research Database Group. , 1994, The Journal of Heart and Lung Transplantation.
[11] J. Losman. The International Society for Heart Transplantation , 1982 .
[12] C. F. Wong,et al. Cardiorenal syndrome - a new classification and current evidence on its management. , 2010, Clinical nephrology.
[13] N. Smedira,et al. The effect of combined Angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[14] F. Pagani,et al. Left ventricular assist device therapy improves utilization of donor hearts. , 2002, Journal of the American College of Cardiology.
[15] M. Mehra,et al. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. , 1995, The American journal of cardiology.
[16] A. Kfoury,et al. Temporal trends in heart transplantation from high-risk donors: are there lessons to be learned? A multi-institutional analysis. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[17] A. Rahmel,et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report--2010. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[18] G. Fonarow,et al. Use of two recipient lists for adults requiring heart transplantation. , 2003, The Journal of thoracic and cardiovascular surgery.
[19] D. Zimpfer,et al. Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. , 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[20] M. Fishbein,et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[21] R. Patten,et al. The effect of ventricular assist devices on post-transplant mortality an analysis of the United network for organ sharing thoracic registry. , 2009, Journal of the American College of Cardiology.
[22] A. Jatene,et al. Prostacyclin in the management of pulmonary hypertension after heart transplantation. , 1990, The Journal of heart transplantation.
[23] D. Holmes,et al. Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy. , 2006, Transplantation.
[24] A. Dipchand,et al. Minimizing infection and rejection death: clues acquired from 19 years of multi-institutional cardiac transplantation data. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[25] A. Khaghani,et al. Transplantation using hearts from primary pulmonary hypertensive donors for recipients with a high pulmonary vascular resistance. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[26] H. Bittner,et al. Hemodynamic and inotropic effects of milrinone after heart transplantation in the setting of recipient pulmonary hypertension. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[27] D. Renlund,et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[28] A. Angelini,et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[29] M. Mehra,et al. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. , 1995, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[30] G. Faggian,et al. Impact of donor quality on outcome of heart transplantation. , 2010, European Journal of Cardio-Thoracic Surgery.
[31] A. Kfoury,et al. Changing outcomes in patients bridged to heart transplantation with continuous- versus pulsatile-flow ventricular assist devices: an analysis of the registry of the International Society for Heart and Lung Transplantation. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[32] Clive Lewis,et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[33] E. Tuzcu,et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.